Abstract:Background: Rapid advancements in cell-free DNA (cfDNA) based liquid biopsy (LB), has opened avenues of critical clinical importance. Recent discovery of a novel class of cell-free DNA 40-70 bps in length, ultrashort cfDNA (uscfDNA) is demonstrating immense potential as a cancer early detection biomarker. Globally, oral cavity squamous cell carcinomas (OCSCC) make up a significant proportion of head and neck squamous cell cancers. OCSCC commonly arises after the occurrence of oral premalignant lesions (OPLs), making it an ideal target for plasma-based LB screening initiatives. Methods: Current work focuses on preferential extraction of low molecular weight nucleic acids and single-stranded library preparation and sequencing, Broad Range cell-free DNA- Sequencing (BRcfDNA-Seq), to obtain uscf- & 167 bps mononucleosomal cfDNA (mncfDNA), for disease detection. Sequencing data was bioinformatically processed: paired-end reads merged (BBmerge), aligned with BWA-mem, deduplicated using SRSLY UMI, and blacklisted portions removed. This was followed by analysis for non-mutational features like fragmentomics, occurrence of G-Quad structures, 4-mer Motif sequences at the end of cfDNA sequences, functional genomic element peak formation by uscfDNA. These features have been recently described non-mutation metrics which have demonstrated evidence of clinical relevance. With non-mutational multi-modal analysis of uscfDNA, obtained using BRcfDNA-Seq, we were able to categorize oral premalignant disorders into two cohorts: one which progressed into OCSCC (PG-OPL) (n=19) & one which did not (nPG-OPL) (n=19). Results: Bioinformatic processing for fragmentomics, of the relative proportion of 40-53bps fragments to 54-70bps fragments in the uscfDNA population demonstrated a significant difference across 1700 chromosomal bins between PG & nPG-OPL (multiple t test, FDR 10%, p value = 0.044, AUROC = 0.7258). The occurrence of G-quadruplex structures in uscfDNA was also significantly different between the two groups (student t test, p= 0.02, AUROC= 0.6953). Examination of the end-motifs profiles of uscfDNA between PG-OPL & nPG-OPL samples showed the randomness of the motifs as revealed by the Shannon entropy score is significant between the two groups (p = 0.046, AUROC = 0.6482). We further evaluated individual motifs that could discriminate between the two groups and identified CCCC, CCCT, TGGG, etc. are highly discriminatory. uscfDNA contained a substantially higher proportion of functional genomic element sequences in the PG-OPL group than the nPG-OPL group like exon (p = 0.00067, AUROC = 0.7147) & 5' UTR (p= 0.000006, AUROC= 0.7673) are different between the groups. Conclusion: Results demonstrated clinical relevance of BRcfDNA-Seq for plasma-derived cfDNA in assessment of malignancy progression of OPLs. These non-mutational multi-modal features of cfDNA maybe indicative of local and systemic factors associated with disease affecting cfDNA. Citation Format: Neeti Swarup, Jordan C. Cheng, Irene Choi, Mohammad Arshad Aziz, Kelly Y. Liu, Fang Wei, Feng Li, Yong Kim, Catherine Poh, David T. Wong. Triaging oral premalignant lesions: Plasma ultrashort cell-free DNA-based liquid biopsy approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB102.

Abstract LB004: Ultra-sensitive targeted DNA panel for very low-frequency mutation detection in circulating cell-free DNA

Abstract 320: Development and automation of a streamlined targeted enrichment method for cancer mutation detection

Abstract 3684: Comprehensive error suppressing approach allowing enhanced minimal residual disease detection in lung cancer patients

Abstract 2141: Development of a highly-sensitive targeted cell-free DNA epigenomic assay for early-stage multi-cancer screening

Abstract 252: A single-tube approach for detection of circulating tumor DNA using customized panels

Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research.

Abstract B071: Detecting Ultra Low-Frequency Variants and Fusions Using a Novel Amplicon-Based Accu-CometTM Method

Abstract 323: Optimization of a liquid biopsy assay to accommodate low cfDNA samples and increase throughput

Abstract 5027: Simplified selective electrochemical detection of ctDNA differentiates between cancer progression and regression

Detecting Ultralow Frequency Mutation in Circulating Cell‐Free DNA of Early‐Stage Nonsmall Cell Lung Cancer Patients with Unique Molecular Identifiers

Abstract 2428: Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Abstract 5026: Microfluidic capillary electrophoresis optimization of high-throughput cfDNA and pDNA measurements for enabling cancer diagnostics and gene therapy development

Abstract 6258: Inference of gene expression using fragmentation patterns from targeted high-depth sequencing of cell-free DNA

Abstract LB102: Triaging oral premalignant lesions: Plasma ultrashort cell-free DNA-based liquid biopsy approach

Abstract 5014: Analytical validation of a complete system for detection and characterization of genomic aberrations in circulating tumor DNA

Abstract 5024: Analytical performance of a genome-wide methylome enrichment platform to detect minimal residual disease from plasma-derived cell-free DNA

Abstract 3685: Improved detection of minimal residual disease in colorectal cancer patients using adaptive noise cancellation algorithm

Abstract 5021: Circulating mutated and methylated tumor DNA detection for colorectal cancer diagnosis

Abstract 6560: Cell-free RNA analysis for non-invasive cancer detection and characterization

Ultrafast and Highly Specific Detection of One-Base Mutated Cell-Free DNA at a Very Low Abundance

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA